SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$2.64 USD
0.00 (0.00%)
Updated May 31, 2024 04:00 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for SAB Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 57 | 15 | 40 | 0 | -99,999 |
Receivables | 0 | 6 | 8 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 2 | 1 | 1 | 0 | NA |
Total Current Assets | 59 | 22 | 48 | 0 | NA |
Net Property & Equipment | 20 | 23 | 24 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 4 | 4 | 4 | 0 | NA |
Total Assets | 84 | 51 | 79 | 0 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 1 | 1 | 0 | 0 | NA |
Accounts Payable | 1 | 4 | 4 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 7 | 10 | 12 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 1 | 0 | 6 | 0 | NA |
Total Current Liabilities | 11 | 15 | 25 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 1 | 0 | 0 | NA |
Non-Current Capital Leases | 3 | 4 | 4 | 0 | NA |
Other Non-Current Liabilities | 12 | 0 | 11 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 27 | 20 | 41 | 0 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 153 | 84 | 68 | 0 | NA |
Retained Earnings | -90 | -48 | -29 | 0 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 6 | 6 | 0 | 0 | NA |
Total Shareholder's Equity | 57 | 31 | 39 | 0 | NA |
Total Liabilities & Shareholder's Equity | 84 | 51 | 79 | 0 | NA |
Total Common Equity | 57 | 31 | 39 | 0 | 0 |
Shares Outstanding | 9.20 | 4.30 | 4.30 | 1.20 | NA |
Book Value Per Share | 6.23 | 7.22 | 8.97 | 0.02 | 0.00 |
Fiscal Year End for SAB Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 44 | 57 | 2 | 8 | 13 |
Receivables | 0 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 2 | 1 | 1 | 1 |
Total Current Assets | 47 | 59 | 3 | 9 | 15 |
Net Property & Equipment | 18 | 20 | 21 | 22 | 22 |
Investments & Advances | 1 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 4 | 4 | 4 | 4 |
Total Assets | 71 | 84 | 28 | 35 | 43 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 1 | 1 | 1 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 7 | 5 | 6 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 2 | 3 | 3 |
Total Current Liabilities | 8 | 11 | 9 | 11 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 1 | 1 |
Non-Current Capital Leases | 3 | 3 | 3 | 3 | 4 |
Other Non-Current Liabilities | 6 | 0 | 1 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 19 | 27 | 13 | 16 | 18 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 153 | 153 | 88 | 87 | 85 |
Retained Earnings | -95 | -90 | -67 | -62 | -55 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 6 | 6 | 6 | 6 | 6 |
Total Shareholder's Equity | 53 | 57 | 15 | 20 | 24 |
Total Liabilities & Shareholder's Equity | 71 | 84 | 28 | 35 | 43 |
Total Common Equity | 53 | 57 | 15 | 20 | 24 |
Shares Outstanding | 9.20 | 9.20 | 5.20 | 5.00 | 5.00 |
Book Value Per Share | 5.74 | 6.23 | 2.93 | 3.94 | 4.88 |